Skip to main content

Chronic Diarrhea

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

NGM Biopharmaceuticals
1 program
1
AldaferminPhase 21 trial
Active Trials
NCT05130047Completed30Est. Nov 2022
ADEL
ADELKorea - Seoul
1 program
An Audit on Management of Chronic DiarrheaN/A1 trial
Active Trials
NCT03269305Completed100Est. Sep 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NGM BiopharmaceuticalsAldafermin
ADELAn Audit on Management of Chronic Diarrhea

Clinical Trials (2)

Total enrollment: 130 patients across 2 trials

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Start: Dec 2021Est. completion: Nov 202230 patients
Phase 2Completed
NCT03269305ADELAn Audit on Management of Chronic Diarrhea

An Audit on Management of Chronic Diarrhea

Start: Sep 2017Est. completion: Sep 2018100 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.